Clinical trials: Polypoidal Choroidal Vasculopathy
Neovascular Polypoidal Choroidal Vasculopathy
Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)
The purpose of this study is to evaluate the safety and efficacy of intravitreal aflibercept injection (IAI) in patients with neovascular polypoidal choroidal vasculopathy.
- Trial name
- RIVAL (NCT02092532)
- Testing
- Rescue Intravitreal Aflibercept Injection, Rescue Therapy with PDT, Laser or Intravitreal Steroids
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Polypoidal Choroidal Vasculopathy
Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)
This is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal choroidal vasculopathy as diagnosed by fluoresceins/indocyanine green (FA/ICG) angiography.
- Trial name
- PEARL (NCT00424710)
- Testing
- ranibizumab intravitreal injection
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Hawaii Pacific Health
Polypoidal Choroidal Vasculopathy
Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
This Phase I/II study will investigate the safety and tolerability of intravitreally administered 0.5mg and 1.0 or 2.0mg Ranibizumab in three monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and…
- Trial name
- NCT01469156
- Testing
- ranibizumab 0.5 or 2.0 mg/0.05 cc
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Polypoidal Choroidal Vasculopathy
Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy
Monthly, continuous anti-vegf therapy for patients presenting with active polypoidal choroidal vasculopathy. Two arms, treatment naive and previously treated with an FDA approved anti-VEGF therapy, will be randomized and dosed…
- Trial name
- PEARL2 (NCT01248117)
- Testing
- ranibizumab 2.0mg
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Retina Consultants of Hawaii
Polypoidal Choroidal Vasculopathy
Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
This Phase I/II safety study is designed to investigate the safety and efficacy of ranibizumab (Lucentis) in the treatment of polypoidal choroidal vasculopathy (PCV), a potentially blinding eye disease that involves the growth of…
- Trial name
- NCT00837330
- Testing
- ranibizumab 0.5 or 0.3 mg/0.05 cc
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Age-Related Macular Degeneration
LOC387715/HTRA1 Variants in Polypoidal Choroidal Vasculopathy in a Korean Population
This study is to investigate whether variants in the LOC387715 locus and the HtrA serine peptidase 1 (HTRA1) gene within the 10q26 locus are associated with polypoidal choroidal vasculopathy and whether they are associated with…
- Trial name
- PCV (NCT01108250)
- Testing
- LOC387715/HTRA1 genotyping
- Where
- South Korea
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- Kyungpook National University Hospital
Symtomatic Macular Polypoidal Choroidal Vasculopathy
Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)
Objective: To evaluate the efficacy of intravitreal aflibercept injection on visual acuity in patients with symptomatic macular PCV.
- Trial name
- NCT02860858
- Testing
- Intravitreous aflibercept injection
- Where
- Thailand
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Wet Macular Degeneration
Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy
The purpose of this study is to evaluate the effects and safety of ranibizumab therapy combined with TA versus ranibizumab monotherapy in patients with polypoidal choroidal vasculopathy (PCV).
- Trial name
- RANTA (NCT02806752)
- Testing
- Triamcinolone Acetonide, Ranibizumab
- Where
- 7 sites in China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Aier School of Ophthalmology, Central South University
Uveitis, Diabetic Retinopathy
Biomarkers of Common Eye Diseases
To identify biomarkers of common eye diseases based on single-cell sequencing technologies using PBMC samples. These diseases include uveitis, diabetic retinopathy, age-related macular degeneration and polypoid choroidal…
- Conditions
- Uveitis, Diabetic Retinopathy, Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
- Trial name
- NCT04101604
- Testing
- Collection of blood samples
- Where
- China
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Polypoidal Choroidal Vasculopathy
Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation
To evaluate the efficacy and safety of intravitreal aflibercept injection in the treatment of PCV
- Trial name
- EPIC (NCT01871376)
- Testing
- Intravitreal aflibercept injection 2.0mg
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Gregg T. Kokame, MD
Polypoidal Choroidal Vasculopathy
Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy
This is a prospective, comparative control analysis. The investigators want to evaluate the aqueous humor levels of vascular endothelial growth factor in polypoidal choroidal vasculopathy and the effect of photodynamic therapy…
- Trial name
- NCT01360151
- Testing
- ranibizumab(Lucentis), verteporfin(Visudyne)
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Seoul St. Mary's Hospital